ストックスクリーナーアプリを入手
9.13
0.22%
-0.02
プレマーケット:
9.13
前日終値:
$9.15
開ける：
$9.2
24時間の取引高:
617.51K
Relative Volume:
0.58
時価総額：
$536.04M
収益：
$106.47M
当期純損益:
$82.89M
株価収益率:
6.1127
EPS:
1.4936
ネットキャッシュフロー:
$-2.43M
1週間 パフォーマンス:
-4.40%
1か月 パフォーマンス:
+2.24%
6か月 パフォーマンス:
-4.10%
1年 パフォーマンス:
+12.02%
1日の値動き範囲:
$9.09
$9.39
1週間の範囲:
$9.02
$9.55
52週間の値動き範囲:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Compare ZVRA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.13 | 536.04M | 106.47M | 82.89M | -2.43M | 1.4936 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | BTIG Research | Buy |
| 2025-07-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-08 | 再開されました | Cantor Fitzgerald | Overweight |
| 2024-10-07 | 開始されました | Guggenheim | Buy |
| 2024-09-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-24 | 繰り返されました | Maxim Group | Buy |
| 2024-04-02 | 繰り返されました | Maxim Group | Buy |
| 2024-03-12 | 開始されました | William Blair | Outperform |
| 2023-03-17 | 開始されました | Maxim Group | Buy |
すべてを表示
Zevra Therapeutics Inc (ZVRA) 最新ニュース
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
How (ZVRA) Movements Inform Risk Allocation Models - Stock Traders Daily
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - MSN
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zevra shares jump after selling SDX portfolio for $50M - MSN
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra Ties NPC Testing Push To Valuation Gap And New CFO - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-03-21 14:23:45 - baoquankhu1.vn
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone - Sahm
New Zevra finance chief gets a 300,000-share stock option - Stock Titan
GeneDx (WGS), Zevra Therapeutics (ZVRA) partner to launch sponsored genetic testing program for NPC - MSN
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC - Yahoo Finance
Zevra Therapeutics announced that, in accordance with Nasdaq Listing Rule 5635(C)(4), it has granted an inducement equity award to the company's new Chief Financial Officer. - Bitget
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant - Stock Titan
Zevra Therapeutics (ZVRA) CFO Justin Renz files insider ownership report - Stock Titan
Zevra Therapeutics appoints Justin Renz as CFO - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook - Investing.com Nigeria
R. LaDuane Clifton (ZVRA) files Form 144 showing 11,000‑ and 3,000‑share sales - Stock Titan
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million and Settles Delaware Lawsuit 1 - Minichart
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpStill a Buy? - MarketBeat
Zevra Therapeutics Agrees to Sell SDX Portfolio to Commave Therapeutics for $50 Million - marketscreener.com
Zevra Shares Jump After Selling SDX Portfolio For $50M - Benzinga
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook By Investing.com - Investing.com Australia
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research - MarketBeat
Zevra Therapeutics (ZVRA) Sells Serdexmethylphenidate Portfolio to Commave for $50 Million - GuruFocus
Zevra Sells SDX Portfolio and Resolves Litigation - TipRanks
Zevra Therapeutics, Inc. $ZVRA Shares Bought by Kingdon Capital Management L.L.C. - MarketBeat
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - Quiver Quantitative
Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million - TradingView
Zevra Sells SDX Portfolio to Commave for $50 Million, Ends Azstarys Pact and Repays Credit Facility - TradingView
ZVRA: BTIG Initiates Coverage with a "Buy" Rating and $23.00 PT - GuruFocus
Zevra (Nasdaq: ZVRA) sells SDX portfolio for $50M and repays $63M loan - Stock Titan
Zevra jumps 19% after Q4 EPS tops consensus estimates - MSN
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress - Sahm
Zevra Therapeutics (NASDAQ:ZVRA) Cut to "Hold" at Wall Street Zen - MarketBeat
Aug Macro: Is Zevra Therapeutics Inc backed by strong institutional buying2026 Key Highlights & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Trading Systems Reacting to (ZVRA) Volatility - Stock Traders Daily
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Analysts Set Expectations for ZVRA Q1 Earnings - MarketBeat
Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing - The Globe and Mail
Zevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by MIPLYFFA Sales - GuruFocus
Trading Action: Should I set a stop loss on Zevra Therapeutics IncEarnings Beat & Daily Profit Focused Screening - baoquankhu1.vn
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C - Zacks Investment Research
Zevra at Citizens Life Sciences: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Zevra Therapeutics Inc (ZVRA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):